MAPT and Alzheimer disease: Although cGMP-dependent CREB activation and memory improvement have been observed following treatment with most PDE5 inhibitors, only a few PDE5 inhibitors have demonstrated reductions in either the amyloid or tau burden, which represent the two neuropathological hallmarks of AD [36].